Shuttle Pharmaceuticals Inc(SHPH),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SHPH Shuttle Pharmaceuticals Inc

Pre-Mkt 06-10 05:17:20 EDT

0.4525

-0.0317

-6.55%

盘前0.4345

-0.0180-3.98%

05:05 EDT

High0.4990	Low0.4300	Vol523.83K
Open0.4730	D1 Closing0.4842	Amplitude14.25%
Mkt Cap2.65M	Tradable Cap2.64M	Total Shares5.85M
T/O240.67K	T/O Rate8.99%	Tradable Shares5.82M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"SHPH","market":"US","secType":"STK","nameCN":"Shuttle Pharmaceuticals Inc","latestPrice":0.4525,"timestamp":1781035200000,"preClose":0.4842,"halted":0,"volume":523832,"hourTrading":{"tag":"盘前","latestPrice":0.4345,"preClose":0.4525,"latestTime":"05:05 EDT","volume":7790,"amount":3412.7612185,"timestamp":1781082347890,"change":-0.018,"changeRate":-0.039779,"amplitude":0.029834},"delay":0,"changeRate":-0.06546881453944652,"floatShares":5823800,"shares":5851290,"eps":-5.7143,"marketStatus":"Pre-Mkt","change":-0.0317,"latestTime":"06-10 05:17:20 EDT","open":0.473,"high":0.49899,"low":0.43,"amount":240665.5501064,"amplitude":0.142482,"askPrice":0.4863,"askSize":100,"bidPrice":0.4345,"bidSize":232,"shortable":0,"etf":0,"ttmEps":-5.7143,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1781098200000},"marketStatusCode":1,"adr":0,"listingDate":1661918400000,"exchange":"NASDAQ","adjPreClose":0.4525,"preHourTrading":{"tag":"盘前","latestPrice":0.4345,"preClose":0.4525,"latestTime":"05:05 EDT","volume":7790,"amount":3412.7612185,"timestamp":1781082347890,"change":-0.018,"changeRate":-0.039779,"amplitude":0.029834},"postHourTrading":{"tag":"盘后","latestPrice":0.43,"preClose":0.4525,"latestTime":"19:57 EDT","volume":11149,"amount":4891.567073,"timestamp":1781049462325,"change":-0.0225,"changeRate":-0.049724,"amplitude":0.049724},"volumeRatio":0.08539957085578719},"requestUrl":"/m/hq/s/SHPH","defaultTab":"news","newsList":[{"id":"2642460830","title":"Shuttle Pharma to execute 10-for-1 reverse stock split on June 11","url":"https://stock-news.laohu8.com/highlight/detail?id=2642460830","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642460830?lang=en_us&edition=fundamental","pubTime":"2026-06-09 20:32","pubTimestamp":1781008372,"startTime":"0","endTime":"0","summary":"Shuttle Pharmaceuticals will implement a 10-for-1 reverse stock split effective June 11, 2026, at 12:01 a.m. ET.Shares will trade on a split-adjusted basis at the June 11 open on Nasdaq under SHPH.Outstanding common shares will drop to about 637,108 from 6,371,075, excluding rounding.Fractional share entitlements will be rounded up to the next whole share.The move targets Nasdaq listing compliance, while reshaping the company’s capital structure.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260609:nNDLchbkH1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SHPH","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640796078","title":"Shuttle Pharmaceuticals files Form 3 for Co-CEO Ryan Trasolini","url":"https://stock-news.laohu8.com/highlight/detail?id=2640796078","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640796078?lang=en_us&edition=fundamental","pubTime":"2026-06-02 07:12","pubTimestamp":1780355536,"startTime":"0","endTime":"0","summary":"Shuttle Pharmaceuticals said Co-Chief Executive Officer Ryan Trasolini filed an initial statement of beneficial ownership on May 6, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shuttle Pharmaceuticals Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 01, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nNDL706w9b:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SHPH","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638838716","title":"Shuttle Pharmaceuticals shareholders approve reverse stock split authorization at annual meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2638838716","media":"Reuters","labels":["shareholding","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638838716?lang=en_us&edition=fundamental","pubTime":"2026-05-27 21:02","pubTimestamp":1779886953,"startTime":"0","endTime":"0","summary":"Shuttle Pharmaceuticals Holdings held its annual shareholder meeting on May 21, 2026.An advisory vote backed the pay packages for the company’s named executive officers.Shareholders authorized the board to pursue a reverse stock split within a 1-for-2 to 1-for-150 range; no split was confirmed as executed.Shareholders also authorized adjournment of the meeting, though it was not required.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shuttle Pharmaceuticals Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 27, 2026, and is solely responsible for the information contained ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nNDL8rvdv5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SHPH","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635866055","title":"Shuttle Pharmaceuticals Q1 EPS $(0.43) Up From $(7.60) YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2635866055","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635866055?lang=en_us&edition=fundamental","pubTime":"2026-05-16 06:19","pubTimestamp":1778883557,"startTime":"0","endTime":"0","summary":"Shuttle Pharmaceuticals (NASDAQ:SHPH) reported quarterly losses of $(0.43) per share. This is a 94.34 percent increase over losses of $(7.60) per share from the same period last year.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52620267/shuttle-pharmaceuticals-q1-eps-0-43-up-from-7-60-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Shuttle Pharmaceuticals Q1 EPS $(0.43) Up From $(7.60) YoY","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QYLG","IYW","NQmain","QQQY","QQQJ",".IXIC","TQQY","QQQM","MNQmain","QQQA","GPIQ","NVIW.SI","FTEC","NDX","BK4139","QQQE","TECS","QLD","SHPH","ONEQ","JEPQ","QID","SQQQ","QDTE","TQQQ","QQQ","PSQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635903073","title":"Shuttle Pharma Q1 FY26 net loss narrows 29% to $2.15 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635903073","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635903073?lang=en_us&edition=fundamental","pubTime":"2026-05-16 04:39","pubTimestamp":1778877591,"startTime":"0","endTime":"0","summary":"Shuttle Pharmaceuticals posted a net loss of USD 2.15 million for the quarter ended March 31, 2026, narrowing 29%.Operating loss tightened 25% to USD 2.22 million on total operating expenses of USD 2.22 million.Research and development expense fell 83% to 267,240, while general and administrative costs rose 94% to USD 1.16 million.Cash and cash equivalents totaled USD 1.09 million, down 76%, with operating cash outflow of USD 2.42 million.Company closed a March 9 underwritten public offering, generating USD 3.5 million in gross proceeds and using USD 1.25 million of net proceeds for marketing efforts tied to Molecule.ai.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shuttle Pharmaceuticals Holdings Inc. published the original content ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nNDL8dfX9s:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SHPH","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633120649","title":"Shuttle Pharmaceuticals closes United Dogecoin acquisition, creating public Dogecoin miner platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2633120649","media":"Reuters","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633120649?lang=en_us&edition=fundamental","pubTime":"2026-05-08 02:03","pubTimestamp":1778176981,"startTime":"0","endTime":"0","summary":"Shuttle Pharmaceuticals completed acquisition of United Dogecoin via merger of United Dogecoin into a wholly owned Shuttle subsidiary, creating one of largest publicly traded Dogecoin mining platforms.Transaction included concurrent USD 9.6 million PIPE financing, closed May 6, 2026, to fund scale-up of mining operations.Next-generation ElphaPex mining rigs expected to be fully operational within 60 days, targeting up to 43,200 GH/s hash rate.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nNDL1xnQBt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","IE00B3QW5Z07.USD","LU0314104364.USD","BK4112","IE00BN0W2W23.USD","LU2210150020.SGD","SHPH","BK4585","SG9999014013.SGD","LU2095319765.USD","NDAQ","IE00BN0W2V16.EUR","IE00BKPKM429.USD","SG9999014039.USD","IE00BN0W2T93.GBP","LU2210149790.SGD","SG9999014005.SGD","BK4139","IE00BGHQF748.EUR","BK4588","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633120664","title":"E.f. Hutton & Co. Serves as Exclusive M&a Advisor and Placement Agent on Completed Shuttle Pharmaceuticals–United Dogecoin Merger to Create the Largest Public Dogecoin Miner","url":"https://stock-news.laohu8.com/highlight/detail?id=2633120664","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633120664?lang=en_us&edition=fundamental","pubTime":"2026-05-08 02:02","pubTimestamp":1778176954,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nTUA2SVFGM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SHPH","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632176946","title":"Shuttle Pharmaceuticals agrees to merge with Dogecoin miner United Dogecoin","url":"https://stock-news.laohu8.com/highlight/detail?id=2632176946","media":"Reuters","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632176946?lang=en_us&edition=fundamental","pubTime":"2026-05-01 21:25","pubTimestamp":1777641912,"startTime":"0","endTime":"0","summary":"Shuttle Pharmaceutical entered definitive merger agreement to acquire Dogecoin miner United Dogecoin, which will become wholly owned subsidiary.Consideration includes 8,000 shares of Series B-1 Convertible Preferred Stock, convertible at USD 1.24 into about 32,258,064 common shares, subject to stockholder approval.Deal also provides up to 118,038,551 pre-funded warrants tied to post-closing operational milestones, issuable only if stockholder approval is obtained.Post-merger board plans to appoint United Dogecoin CEO Ryan Trasolini as co-CEO alongside Christopher Cooper, with CFO Yuying Liang continuing.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shuttle Pharmaceuticals Holdings Inc. published the original content used to generate ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260501:nNDL69WK9G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SHPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626143921","title":"Shuttle Pharmaceuticals announces annual shareholder meeting via webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2626143921","media":"Reuters","labels":["shareholding","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626143921?lang=en_us&edition=fundamental","pubTime":"2026-04-11 05:13","pubTimestamp":1775855615,"startTime":"0","endTime":"0","summary":"Shuttle Pharmaceuticals scheduled 2026 annual shareholder meeting for May 21, 2026 via live webcast.Shareholders will vote on election of five directors.Advisory vote will be held on executive compensation.Investors will also consider authorizing board to implement one or more reverse stock splits within 1-for-2 to 1-for-150 range, plus approval to adjourn meeting if needed to secure votes.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shuttle Pharmaceuticals Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 10, 2026, and is solely responsible for the information contai","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260410:nNDL9j41Ws:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SHPH","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624537708","title":"Shuttle Pharma FY25 net loss widens 28% to $11.7 million; operating loss deepens to $11.9 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2624537708","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624537708?lang=en_us&edition=fundamental","pubTime":"2026-04-01 04:16","pubTimestamp":1774988212,"startTime":"0","endTime":"0","summary":"Shuttle Pharmaceuticals posted a net loss of USD 12 million for fiscal year 2025, widening 28%.Revenue was unchanged at no revenue, while operating loss expanded to USD 12 million.Research and development expense rose 12% to USD 4.1 million, while general and administrative expense more than quadrupled to USD 5.7 million.Completed acquisition of Molecule.ai assets in November, paying USD 3 million in cash; committed to wind down ropidoxuridine clinical trials.Outlook: future research and development activities expected to cease until it determines direction of preclinical and clinical drug development efforts.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shuttle Pharmaceuticals Holdings Inc. published the original content used to gen","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nNDLbYgfyY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SHPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622876306","title":"BUZZ-U.S. STOCKS ON THE MOVE-Entergy, IDEX Corp, Quanta Services","url":"https://stock-news.laohu8.com/highlight/detail?id=2622876306","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622876306?lang=en_us&edition=fundamental","pubTime":"2026-03-27 23:48","pubTimestamp":1774626488,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Entergy, IDEX Corp, Quanta Services Workspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsl","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nL6N40F0XI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGX","ETR","CCL.UK","ANAB","IEX","SHPH","CONX","HKIT","AME","HON","ITRM","GGLS","FCHL","CRWD","WIX","BTGO","ZBIO","FTNT","DDOG","VATE","CONI","ADMA","SAIL","SST","FIAT","DISO","PHAT","ITRMF","PH","DIS","DTCX","BKSY","TWO","ICOI","02026","PANW","GGLL","RCKT","ETN","EMR","DOV","LTRN","ARTL","PWR","VOR","CCL","FPS"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2618134207","title":"Shuttle Pharmaceuticals closes USD 3.5 million public offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2618134207","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618134207?lang=en_us&edition=fundamental","pubTime":"2026-03-12 20:31","pubTimestamp":1773318692,"startTime":"0","endTime":"0","summary":"Shuttle Pharmaceuticals announced a public offering expected to raise gross proceeds of about 3.5 million, before fees and expenses. The company agreed to issue 2,238,800 common shares and pre-funded warrants to buy 4,761,200 common shares. E.F. Hutton is serving as exclusive placement agent for the offering. Shuttle Pharmaceuticals said it plans to allocate up to 1.5 million of net proceeds to future marketing and the remainder to working capital and general corporate purposes.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nNDL6JZfkP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","LU2210150020.SGD","SG9999014021.USD","IE00B3QW5Z07.USD","IE00BKPKM429.USD","NDAQ","SHPH","BK4139","IE00B64PRP62.GBP","LU0314104364.USD","SG9999014013.SGD","LU2210149790.SGD","SG9999014005.SGD","BK4585","BK4112","BK4588","SG9999014039.USD","IE00BGHQF748.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618961466","title":"Shuttle Pharmaceuticals announces USD 3.5 million public offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2618961466","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618961466?lang=en_us&edition=fundamental","pubTime":"2026-03-11 05:01","pubTimestamp":1773176487,"startTime":"0","endTime":"0","summary":"Shuttle Pharma said it entered a securities purchase agreement for a public offering expected to raise about USD 3.5 million in gross proceeds. The offering includes 2.24 million shares of common stock and pre-funded warrants to buy 4.76 million shares. E.F. Hutton is acting as exclusive placement agent. Shuttle Pharma said it expects to use up to USD 1.5 million of the net proceeds for future marketing efforts, with the remainder for working capital and general corporate purposes. The offering is being made pursuant to a registration statement on Form S-1 available at www.sec.gov.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shuttle Pharmaceuticals Holdings Inc. published the original content used to generate this news brief via EDG","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nNDLbsypyc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SHPH","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612765495","title":"Shuttle Pharma FY2025 general and administrative expenses surge to USD 5.2–5.8 million from USD 1.4 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2612765495","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612765495?lang=en_us&edition=fundamental","pubTime":"2026-02-18 06:21","pubTimestamp":1771366904,"startTime":"0","endTime":"0","summary":"Shuttle Pharmaceuticals Holdings Inc. reported a preliminary net loss for full year 2025 in the range of USD 10.86 million to USD 12.08 million. The company recorded no revenue for the period. Research and development expenses are estimated between USD 3.42 million and USD 3.85 million, remaining relatively stable year-over-year. General and administrative expenses are expected between USD 5.23 million and USD 5.78 million, driven primarily by increased investor relations advertising costs of USD 3.6 million. Shuttle Pharmaceuticals anticipates a decrease in research and development activities pending future decisions on its preclinical and clinical drug development programs.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shuttle Pharm","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nNDL282kGr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SHPH","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608057813","title":"Shuttle Pharmaceuticals Extends Consulting Agreement With Interim Co-CEO at $20,000 Per Month","url":"https://stock-news.laohu8.com/highlight/detail?id=2608057813","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608057813?lang=en_us&edition=fundamental","pubTime":"2026-02-03 06:21","pubTimestamp":1770070866,"startTime":"0","endTime":"0","summary":"Shuttle Pharmaceuticals Holdings Inc. has amended its consulting agreement with Number 2 Capital Corp., a Canadian entity owned by interim co-Chief Executive Officer Christopher Cooper. Effective September 11, 2025, the agreement extends the consulting term to August 1, 2026, with compensation set at $20,000 per month. The agreement requires a 40-hour work week and includes standard confidentiality and non-disclosure provisions. Either party may terminate the agreement with 30 days' notice, or immediately for cause.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shuttle Pharmaceuticals Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nNDL9JZFMB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SHPH","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603529692","title":"Shuttle Pharmaceuticals Names Yuying Liang as Finance Chief","url":"https://stock-news.laohu8.com/highlight/detail?id=2603529692","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603529692?lang=en_us&edition=fundamental","pubTime":"2026-01-13 05:47","pubTimestamp":1768254420,"startTime":"0","endTime":"0","summary":"Shuttle Pharmaceuticals named Yuying Liang as its next chief financial officer.Liang will succeed Chris Cooper, who will continue to serve as interim chief executive, the cancer treatment company said Monday.Liang, 35, has been working with the company via her company Yuying Liang Professional, where she has been performing bookkeeping, accounting and financial reporting.Liang is a certified public accountant who has worked with public and private companies across multiple sectors. Most recently, she was named chief financial officer of iSpecimen in December 2024.Liang also currently serves as chief financial officer of BlockchainK2, Goldhills Holding, Intact Gold, Kincora Copper, Transatlantic Mining and Ultra Brands. She is chief financial officer and director at Modern Plant Based Foods and Montego Resources.Shuttle plans to pay Liang a monthly fee of $15,000 plus taxes, it said.Separately, Sachin Pathigoda resigned from his position on the company's board of directors. The board ha","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SHPH","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603526120","title":"BRIEF-Shuttle Pharmaceuticals Holdings Inc - Appoints Yuying Liang As CFO - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2603526120","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603526120?lang=en_us&edition=fundamental","pubTime":"2026-01-13 05:20","pubTimestamp":1768252802,"startTime":"0","endTime":"0","summary":"BRIEF-Shuttle Pharmaceuticals Holdings Inc - Appoints Yuying Liang As CFO - SEC FilingJan 12  - SEC Filing:SHUTTLE PHARMACEUTICALS HOLDINGS INC - APPOINTS YUYING LIANG AS CFO - SEC FILINGSource text: [ID:n0001493152-26-001861]Further company coverage: SHPH.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nFWN3YD0UG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SHPH","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603526987","title":"Shuttle Pharmaceuticals Holdings Inc. Files Initial Beneficial Ownership Statement for CFO Yuying Liang","url":"https://stock-news.laohu8.com/highlight/detail?id=2603526987","media":"Reuters","labels":["executive","shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603526987?lang=en_us&edition=fundamental","pubTime":"2026-01-13 05:15","pubTimestamp":1768252553,"startTime":"0","endTime":"0","summary":"Shuttle Pharmaceuticals Holdings Inc. has filed an initial statement of beneficial ownership with the U.S. Securities and Exchange Commission. The filing lists Yuying Liang, the company’s Chief Financial Officer, as the beneficial owner. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shuttle Pharmaceuticals Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 12, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL993RMP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Shuttle Pharmaceuticals Holdings Inc. Files Initial Beneficial Ownership Statement for CFO Yuying Liang","news_tag":"executive,shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SHPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2595758433","title":"Shuttle Pharmaceuticals Issues 320,496 Unregistered Shares in Asset Purchase Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2595758433","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595758433?lang=en_us&edition=fundamental","pubTime":"2025-12-30 05:06","pubTimestamp":1767042388,"startTime":"0","endTime":"0","summary":"Shuttle Pharmaceuticals Holdings Inc. has announced the accelerated issuance of 320,496 shares of its common stock as part of a private placement under the terms of an amended asset purchase agreement. The shares, issued at a value of $1.76 each, represent approximately 19.99% of the company’s outstanding common stock as of the closing date. The offering was made pursuant to exemptions from registration under the Securities Act, specifically Section 4, Rule 506, and Regulation S. The transaction’s remaining payment obligations will be settled in cash according to the agreement’s terms.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shuttle Pharmaceuticals Holdings Inc. published the original content used to generate this news brief via","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251229:nNDLc5rVh7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SHPH"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.shuttlepharma.com","stockEarnings":[{"period":"1week","weight":-0.1388},{"period":"1month","weight":-0.3434},{"period":"3month","weight":-0.4976},{"period":"6month","weight":-0.7472},{"period":"1year","weight":-0.9062},{"period":"ytd","weight":-0.7486}],"compareEarnings":[{"period":"1week","weight":-0.0296},{"period":"1month","weight":-0.0008},{"period":"3month","weight":0.0898},{"period":"6month","weight":0.0695},{"period":"1year","weight":0.2291},{"period":"ytd","weight":0.0808}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas, SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers. The company was founded in 2012 and is based in Rockville, Maryland.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.048599},{"month":2,"riseRate":0.5,"avgChangeRate":-0.170656},{"month":3,"riseRate":0.25,"avgChangeRate":-0.234438},{"month":4,"riseRate":0.75,"avgChangeRate":0.112025},{"month":5,"riseRate":0.25,"avgChangeRate":-0.214772},{"month":6,"riseRate":0.25,"avgChangeRate":-0.12206},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.082532},{"month":8,"riseRate":0,"avgChangeRate":-0.223531},{"month":9,"riseRate":0.25,"avgChangeRate":-0.322851},{"month":10,"riseRate":0.25,"avgChangeRate":-0.104427},{"month":11,"riseRate":0.25,"avgChangeRate":-0.361431},{"month":12,"riseRate":0.75,"avgChangeRate":0.133405}],"exchange":"NASDAQ","name":"Shuttle Pharmaceuticals Inc","nameEN":"Shuttle Pharmaceuticals Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Shuttle Pharmaceuticals Inc(SHPH),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Shuttle Pharmaceuticals Inc(SHPH) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Shuttle Pharmaceuticals Inc,SHPH,Shuttle Pharmaceuticals Inc股票,Shuttle Pharmaceuticals Inc股票老虎,Shuttle Pharmaceuticals Inc股票老虎国际,Shuttle Pharmaceuticals Inc行情,Shuttle Pharmaceuticals Inc股票行情,Shuttle Pharmaceuticals Inc股价,Shuttle Pharmaceuticals Inc股市,Shuttle Pharmaceuticals Inc股票价格,Shuttle Pharmaceuticals Inc股票交易,Shuttle Pharmaceuticals Inc股票购买,Shuttle Pharmaceuticals Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Shuttle Pharmaceuticals Inc(SHPH),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Shuttle Pharmaceuticals Inc(SHPH) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}